Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Study Type-Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Radiation Therapy for prostate cancer can increase the risk for the development of second cancers after treatment. This study highlights the fact that such second cancers within the pelvis do occur but are not as common as previously reported. In this report we also note that even among patients who develop second cancers, if detected earlier, the majority are alive 5 years after the diagnosis.


OBJECTIVE
To report on the incidence of secondary malignancy (SM) development after external-beam radiotherapy (EBRT) and brachytherapy (BT) for prostate cancer and to compare this with a cohort contemporaneously treated with radical prostatectomy (RP).


METHODS
Between 1998 and 2001, 2658 patients with localized prostate cancer were treated with RP (n = 1348), EBRT (n = 897) or BT (n = 413). Using the RP cohort as a control we compared the incidence of SMs, such as rectal or bladder cancers noted within the pelvis, and the incidence of extrapelvic SMs.


RESULTS
The 10-year SM-free survival for the RP, BT and EBRT cohorts were 89%, 87%, and 83%, respectively (RP vs EBRT, P = 0.002; RP vs BT, P = 0.37). The 10-year likelihoods for bladder or colorectal cancer SM development in the RP, BT and EBRT groups were 3%, 2% and 4%, respectively (P = 0.29). Multivariate analysis of predictors for development of all SMs showed that older age (P = 0.01) and history of smoking (P<0.001) were significant predictors for the development of a SM, while treatment intervention was not found to be a significant variable. Among 243 patients who developed a SM, the 5-year likelihood of SM-related mortality among patients with SMs in the EBRT and BT groups was 43.7% and 15.6%, respectively, compared with 26.3% in the RP cohort; (P = 0.052).


CONCLUSIONS
The incidence of SM after radiotherapy was not significantly different from that after RP when adjusted for patient age and smoking history. The incidence of bladder and rectal cancers was low for both EBRT- and BT-treated patients. Among patients who developed a SM, the likelihood of mortality related to the SM was not significantly different among the treatment cohorts.
Alexander
A
Gottschalk
D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D010386:Pelvic Neoplasms / Q000209:etiology*; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000628:therapy*; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*